Bryan Daehahn Choi, M.D.,Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Immunotherapy, Adoptive | 18 | 2024 | 1505 | 3.680 |
Why?
|
Glioblastoma | 25 | 2024 | 3523 | 3.140 |
Why?
|
Brain Neoplasms | 35 | 2024 | 9182 | 2.830 |
Why?
|
Glioma | 14 | 2024 | 3523 | 2.020 |
Why?
|
Antibodies, Bispecific | 7 | 2019 | 204 | 2.010 |
Why?
|
Neurosurgery | 4 | 2022 | 690 | 1.360 |
Why?
|
Receptors, Antigen, T-Cell | 8 | 2024 | 2568 | 1.180 |
Why?
|
T-Lymphocytes | 21 | 2024 | 10273 | 1.010 |
Why?
|
Isocitrate Dehydrogenase | 7 | 2024 | 954 | 0.980 |
Why?
|
Education, Graduate | 2 | 2014 | 75 | 0.860 |
Why?
|
Immunotherapy | 18 | 2024 | 4728 | 0.740 |
Why?
|
Antigens, Neoplasm | 5 | 2024 | 2003 | 0.670 |
Why?
|
Tumor Microenvironment | 8 | 2024 | 3939 | 0.640 |
Why?
|
Cancer Vaccines | 6 | 2016 | 1044 | 0.610 |
Why?
|
Spinal Neoplasms | 3 | 2020 | 715 | 0.600 |
Why?
|
Foreign-Body Migration | 1 | 2018 | 220 | 0.530 |
Why?
|
Meningomyelocele | 1 | 2017 | 182 | 0.510 |
Why?
|
Cerebral Ventricle Neoplasms | 1 | 2013 | 43 | 0.440 |
Why?
|
Academic Medical Centers | 2 | 2014 | 2785 | 0.430 |
Why?
|
Perforin | 1 | 2013 | 169 | 0.430 |
Why?
|
Granzymes | 2 | 2019 | 279 | 0.430 |
Why?
|
Thoracic Vertebrae | 1 | 2017 | 613 | 0.420 |
Why?
|
Publications | 1 | 2015 | 196 | 0.420 |
Why?
|
T-Lymphocytes, Regulatory | 5 | 2020 | 3108 | 0.420 |
Why?
|
Complementarity Determining Regions | 1 | 2013 | 150 | 0.410 |
Why?
|
Granuloma, Plasma Cell | 1 | 2013 | 80 | 0.410 |
Why?
|
Lateral Ventricles | 1 | 2013 | 145 | 0.400 |
Why?
|
Monitoring, Intraoperative | 3 | 2024 | 952 | 0.400 |
Why?
|
Wounds, Gunshot | 1 | 2018 | 589 | 0.400 |
Why?
|
Education, Medical, Graduate | 3 | 2014 | 2411 | 0.390 |
Why?
|
Indoleamine-Pyrrole 2,3,-Dioxygenase | 1 | 2012 | 117 | 0.390 |
Why?
|
Bibliometrics | 1 | 2015 | 354 | 0.380 |
Why?
|
Cytotoxicity, Immunologic | 2 | 2019 | 1355 | 0.370 |
Why?
|
Antigens, CD19 | 3 | 2024 | 437 | 0.360 |
Why?
|
Xenograft Model Antitumor Assays | 6 | 2024 | 3619 | 0.350 |
Why?
|
Lymphocyte Activation | 7 | 2019 | 5495 | 0.340 |
Why?
|
Cell Line, Tumor | 11 | 2024 | 17149 | 0.330 |
Why?
|
Biomedical Research | 3 | 2014 | 3463 | 0.310 |
Why?
|
Mutation | 8 | 2024 | 30243 | 0.300 |
Why?
|
Tumor Escape | 1 | 2011 | 374 | 0.300 |
Why?
|
Publishing | 1 | 2015 | 836 | 0.300 |
Why?
|
Central Nervous System Neoplasms | 3 | 2022 | 928 | 0.300 |
Why?
|
Neurosurgical Procedures | 6 | 2024 | 2097 | 0.280 |
Why?
|
Humans | 69 | 2024 | 768451 | 0.270 |
Why?
|
Transduction, Genetic | 3 | 2020 | 903 | 0.270 |
Why?
|
Animals | 26 | 2024 | 169418 | 0.260 |
Why?
|
Astrocytoma | 2 | 2024 | 780 | 0.240 |
Why?
|
B-Cell Activating Factor | 2 | 2016 | 116 | 0.230 |
Why?
|
Motor Cortex | 1 | 2012 | 1015 | 0.230 |
Why?
|
Neoplasms | 5 | 2024 | 22386 | 0.220 |
Why?
|
CD8-Positive T-Lymphocytes | 3 | 2024 | 4642 | 0.210 |
Why?
|
Neuronavigation | 1 | 2024 | 169 | 0.210 |
Why?
|
GPI-Linked Proteins | 1 | 2024 | 473 | 0.200 |
Why?
|
Myeloid Cells | 2 | 2024 | 833 | 0.200 |
Why?
|
Dacarbazine | 3 | 2016 | 560 | 0.200 |
Why?
|
Surface Plasmon Resonance | 2 | 2013 | 271 | 0.200 |
Why?
|
Chemokine CCL20 | 1 | 2021 | 64 | 0.190 |
Why?
|
Lymphoma | 2 | 2022 | 1907 | 0.190 |
Why?
|
Receptors, CCR6 | 1 | 2021 | 74 | 0.190 |
Why?
|
Antineoplastic Agents, Alkylating | 3 | 2016 | 618 | 0.190 |
Why?
|
Mice | 16 | 2024 | 82045 | 0.180 |
Why?
|
Efficiency | 2 | 2014 | 477 | 0.180 |
Why?
|
4-1BB Ligand | 1 | 2020 | 29 | 0.180 |
Why?
|
RNA, Small Cytoplasmic | 1 | 2020 | 17 | 0.180 |
Why?
|
Endopeptidases | 1 | 2024 | 772 | 0.170 |
Why?
|
Tumor Necrosis Factor Ligand Superfamily Member 13 | 1 | 2019 | 40 | 0.170 |
Why?
|
Lentivirus | 2 | 2020 | 519 | 0.170 |
Why?
|
Single-Chain Antibodies | 3 | 2018 | 112 | 0.160 |
Why?
|
Protein Engineering | 2 | 2013 | 549 | 0.160 |
Why?
|
Brain Mapping | 2 | 2021 | 6740 | 0.150 |
Why?
|
Internship and Residency | 2 | 2015 | 5952 | 0.150 |
Why?
|
Career Choice | 2 | 2014 | 769 | 0.150 |
Why?
|
Evoked Potentials, Motor | 1 | 2021 | 465 | 0.140 |
Why?
|
Surgery, Plastic | 2 | 2014 | 650 | 0.140 |
Why?
|
Health Resources | 1 | 2023 | 950 | 0.140 |
Why?
|
Mice, Inbred NOD | 3 | 2019 | 1839 | 0.140 |
Why?
|
Antibody Specificity | 3 | 2013 | 1065 | 0.140 |
Why?
|
Disease Models, Animal | 4 | 2024 | 18388 | 0.140 |
Why?
|
Antigen-Presenting Cells | 1 | 2020 | 965 | 0.140 |
Why?
|
Lymphoma, Mantle-Cell | 1 | 2019 | 238 | 0.140 |
Why?
|
Up-Regulation | 2 | 2024 | 4138 | 0.130 |
Why?
|
Fellowships and Scholarships | 2 | 2014 | 1134 | 0.120 |
Why?
|
Proto-Oncogene Proteins c-met | 1 | 2018 | 568 | 0.120 |
Why?
|
Adoptive Transfer | 2 | 2014 | 825 | 0.120 |
Why?
|
Lymphocyte Depletion | 2 | 2013 | 605 | 0.120 |
Why?
|
Tomography, X-Ray Computed | 2 | 2017 | 20762 | 0.110 |
Why?
|
Neoplasms, Experimental | 1 | 2019 | 1232 | 0.110 |
Why?
|
Gene Expression Regulation, Neoplastic | 4 | 2024 | 8635 | 0.110 |
Why?
|
Lung Neoplasms | 1 | 2018 | 13589 | 0.110 |
Why?
|
Craniotomy | 2 | 2021 | 748 | 0.110 |
Why?
|
Combined Modality Therapy | 3 | 2024 | 8559 | 0.110 |
Why?
|
Magnetic Resonance Imaging | 5 | 2024 | 36840 | 0.110 |
Why?
|
Lymphocyte Count | 1 | 2016 | 793 | 0.110 |
Why?
|
Lymphocytes, Tumor-Infiltrating | 2 | 2024 | 1104 | 0.110 |
Why?
|
Chromatography | 1 | 2012 | 189 | 0.110 |
Why?
|
Mice, SCID | 2 | 2019 | 2633 | 0.100 |
Why?
|
Antibody Affinity | 1 | 2013 | 252 | 0.100 |
Why?
|
Indicators and Reagents | 1 | 2013 | 455 | 0.100 |
Why?
|
Flow Cytometry | 2 | 2013 | 5904 | 0.100 |
Why?
|
Chimera | 1 | 2013 | 454 | 0.100 |
Why?
|
Microsurgery | 1 | 2017 | 803 | 0.100 |
Why?
|
Alcohol Oxidoreductases | 1 | 2012 | 164 | 0.100 |
Why?
|
Disease Susceptibility | 1 | 2018 | 1797 | 0.100 |
Why?
|
Antigen-Antibody Complex | 1 | 2013 | 511 | 0.090 |
Why?
|
Convection | 1 | 2011 | 30 | 0.090 |
Why?
|
Treatment Outcome | 10 | 2024 | 65409 | 0.090 |
Why?
|
Oncolytic Viruses | 1 | 2015 | 345 | 0.090 |
Why?
|
Immunotoxins | 1 | 2011 | 175 | 0.090 |
Why?
|
Proto-Oncogene Proteins p21(ras) | 1 | 2018 | 1766 | 0.090 |
Why?
|
Electrophoresis, Polyacrylamide Gel | 1 | 2012 | 1734 | 0.090 |
Why?
|
Mutagenesis, Site-Directed | 1 | 2013 | 1688 | 0.080 |
Why?
|
Socioeconomic Factors | 1 | 2023 | 7863 | 0.080 |
Why?
|
Research Support as Topic | 1 | 2013 | 699 | 0.080 |
Why?
|
Protein-Tyrosine Kinases | 1 | 2018 | 2434 | 0.080 |
Why?
|
Bone Neoplasms | 1 | 2021 | 2562 | 0.080 |
Why?
|
Sequence Alignment | 1 | 2013 | 2184 | 0.080 |
Why?
|
Survival Rate | 2 | 2024 | 12875 | 0.080 |
Why?
|
Standard of Care | 1 | 2013 | 571 | 0.080 |
Why?
|
Prognosis | 5 | 2024 | 30028 | 0.070 |
Why?
|
Kaplan-Meier Estimate | 1 | 2018 | 6537 | 0.070 |
Why?
|
Pancreatic Neoplasms | 1 | 2024 | 5442 | 0.070 |
Why?
|
Leukemia, Myeloid, Acute | 1 | 2022 | 3623 | 0.070 |
Why?
|
T-Lymphocytes, Cytotoxic | 1 | 2013 | 1797 | 0.070 |
Why?
|
Proto-Oncogene Proteins | 1 | 2018 | 4534 | 0.070 |
Why?
|
Models, Molecular | 2 | 2013 | 5443 | 0.070 |
Why?
|
Male | 13 | 2024 | 364781 | 0.060 |
Why?
|
Neoplasm Recurrence, Local | 1 | 2024 | 9425 | 0.060 |
Why?
|
Carcinoma, Renal Cell | 1 | 2020 | 3197 | 0.060 |
Why?
|
Antineoplastic Agents | 3 | 2013 | 13708 | 0.060 |
Why?
|
History, 21st Century | 1 | 2011 | 1575 | 0.060 |
Why?
|
Female | 13 | 2024 | 396943 | 0.060 |
Why?
|
Vaccines, Subunit | 2 | 2016 | 159 | 0.060 |
Why?
|
Kidney Neoplasms | 1 | 2020 | 4298 | 0.060 |
Why?
|
Drug Delivery Systems | 2 | 2012 | 2238 | 0.050 |
Why?
|
Aged | 6 | 2024 | 171520 | 0.050 |
Why?
|
Retrospective Studies | 6 | 2024 | 81834 | 0.050 |
Why?
|
History, 20th Century | 1 | 2011 | 2772 | 0.050 |
Why?
|
Clinical Trials, Phase I as Topic | 1 | 2024 | 330 | 0.050 |
Why?
|
Cross-Sectional Studies | 1 | 2023 | 26351 | 0.050 |
Why?
|
Cell Differentiation | 1 | 2019 | 11674 | 0.050 |
Why?
|
Saccharomyces cerevisiae | 1 | 2012 | 2680 | 0.050 |
Why?
|
Multiple Myeloma | 1 | 2019 | 5192 | 0.050 |
Why?
|
Amino Acid Sequence | 1 | 2013 | 13452 | 0.050 |
Why?
|
Biopsy | 1 | 2013 | 6816 | 0.050 |
Why?
|
United States | 2 | 2023 | 73121 | 0.050 |
Why?
|
Clinical Trials as Topic | 2 | 2024 | 8051 | 0.050 |
Why?
|
Lymphopenia | 2 | 2013 | 290 | 0.050 |
Why?
|
Molecular Sequence Data | 1 | 2013 | 17647 | 0.040 |
Why?
|
Escherichia coli | 1 | 2012 | 4220 | 0.040 |
Why?
|
Neoplasm Transplantation | 2 | 2014 | 2017 | 0.040 |
Why?
|
Signal Transduction | 2 | 2020 | 23638 | 0.040 |
Why?
|
T-Cell Antigen Receptor Specificity | 1 | 2019 | 89 | 0.040 |
Why?
|
Single-Cell Analysis | 2 | 2021 | 2531 | 0.040 |
Why?
|
Telomerase | 1 | 2024 | 751 | 0.040 |
Why?
|
Evoked Potentials, Somatosensory | 1 | 2021 | 247 | 0.040 |
Why?
|
Interleukin-2 | 2 | 2018 | 1894 | 0.040 |
Why?
|
Serine Endopeptidases | 1 | 2024 | 1032 | 0.040 |
Why?
|
Prostatic Neoplasms | 1 | 2021 | 11206 | 0.040 |
Why?
|
K562 Cells | 1 | 2020 | 645 | 0.040 |
Why?
|
Melanoma | 1 | 2017 | 5740 | 0.040 |
Why?
|
Diagnosis, Differential | 1 | 2013 | 13026 | 0.040 |
Why?
|
Middle Aged | 6 | 2024 | 223418 | 0.040 |
Why?
|
Drug Therapy | 1 | 2020 | 504 | 0.040 |
Why?
|
Immunity | 1 | 2023 | 1002 | 0.030 |
Why?
|
Dexamethasone | 1 | 2024 | 1965 | 0.030 |
Why?
|
Adult | 5 | 2024 | 223542 | 0.030 |
Why?
|
Antibodies | 2 | 2016 | 2425 | 0.030 |
Why?
|
Ultrasonography, Interventional | 1 | 2024 | 1519 | 0.030 |
Why?
|
Brain Diseases | 1 | 2024 | 1553 | 0.030 |
Why?
|
Spine | 1 | 2020 | 1142 | 0.030 |
Why?
|
Disease Management | 1 | 2024 | 2533 | 0.030 |
Why?
|
Promoter Regions, Genetic | 1 | 2024 | 5803 | 0.030 |
Why?
|
Carcinoma, Pancreatic Ductal | 1 | 2024 | 1755 | 0.030 |
Why?
|
Vascular Endothelial Growth Factor A | 1 | 2024 | 3520 | 0.030 |
Why?
|
Biocatalysis | 1 | 2012 | 170 | 0.020 |
Why?
|
Tumor Cells, Cultured | 1 | 2019 | 6135 | 0.020 |
Why?
|
Forkhead Transcription Factors | 1 | 2019 | 1625 | 0.020 |
Why?
|
HEK293 Cells | 1 | 2020 | 4294 | 0.020 |
Why?
|
Autoimmunity | 1 | 2019 | 1361 | 0.020 |
Why?
|
Radiosurgery | 1 | 2020 | 1354 | 0.020 |
Why?
|
Interleukin-10 | 1 | 2016 | 1185 | 0.020 |
Why?
|
Catalytic Domain | 1 | 2012 | 709 | 0.020 |
Why?
|
Prospective Studies | 2 | 2024 | 54914 | 0.020 |
Why?
|
Adolescent | 2 | 2019 | 89168 | 0.020 |
Why?
|
Oncolytic Virotherapy | 1 | 2015 | 521 | 0.020 |
Why?
|
Molecular Targeted Therapy | 1 | 2020 | 2834 | 0.020 |
Why?
|
Organ Transplantation | 1 | 2019 | 1177 | 0.020 |
Why?
|
Green Fluorescent Proteins | 1 | 2014 | 2072 | 0.020 |
Why?
|
Mentors | 1 | 2014 | 672 | 0.020 |
Why?
|
Recombinant Proteins | 1 | 2018 | 6527 | 0.020 |
Why?
|
Antigens | 1 | 2013 | 1443 | 0.020 |
Why?
|
Protein Binding | 1 | 2019 | 9376 | 0.020 |
Why?
|
Membrane Proteins | 1 | 2024 | 7895 | 0.020 |
Why?
|
Liposomes | 1 | 2011 | 792 | 0.020 |
Why?
|
Brain | 1 | 2014 | 27438 | 0.020 |
Why?
|
Tissue Distribution | 1 | 2011 | 2298 | 0.020 |
Why?
|
Autoimmune Diseases | 1 | 2019 | 2260 | 0.020 |
Why?
|
Macrophages | 1 | 2021 | 5797 | 0.020 |
Why?
|
Adenocarcinoma | 1 | 2024 | 6400 | 0.020 |
Why?
|
Graft vs Host Disease | 1 | 2019 | 3042 | 0.020 |
Why?
|
Gadolinium | 1 | 2011 | 965 | 0.020 |
Why?
|
Neoplasm Invasiveness | 1 | 2014 | 3637 | 0.020 |
Why?
|
Skin | 1 | 2019 | 4520 | 0.020 |
Why?
|
Cell Line | 1 | 2019 | 15609 | 0.010 |
Why?
|
Data Collection | 1 | 2014 | 3329 | 0.010 |
Why?
|
Cell Membrane | 1 | 2014 | 3664 | 0.010 |
Why?
|
Cytokines | 1 | 2019 | 7449 | 0.010 |
Why?
|
Blood-Brain Barrier | 1 | 2011 | 1034 | 0.010 |
Why?
|
Case-Control Studies | 1 | 2021 | 22293 | 0.010 |
Why?
|
Cell Proliferation | 1 | 2019 | 10494 | 0.010 |
Why?
|
Apoptosis | 1 | 2019 | 9526 | 0.010 |
Why?
|
Cell Survival | 1 | 2013 | 5801 | 0.010 |
Why?
|
Follow-Up Studies | 1 | 2024 | 39430 | 0.010 |
Why?
|
Cell Movement | 1 | 2014 | 5223 | 0.010 |
Why?
|
Phenotype | 1 | 2019 | 16712 | 0.010 |
Why?
|
Mice, Transgenic | 1 | 2013 | 9558 | 0.010 |
Why?
|
Disease Progression | 1 | 2017 | 13655 | 0.010 |
Why?
|
Genetic Testing | 1 | 2013 | 3586 | 0.010 |
Why?
|
Genotype | 1 | 2013 | 13047 | 0.010 |
Why?
|
Young Adult | 1 | 2019 | 60045 | 0.010 |
Why?
|